Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
In a new study, patients taking statins reported experiencing symptoms that were identical to those experienced while taking placebo pills. Researchers suggest that the nocebo effect may be the cause of these side effects, rather than an actual pharmacological effect of the drug.
Researchers found that 90% of symptoms reported by statin users were also experienced when taking a placebo. This suggests a psychological rather than pharmacological effect of statins. Despite concerns about side effects, half of participants restarted taking a statin medication six months after the trial.
A new fish oil-based medication, omega-3 carboxylic acids, did not decrease the risk of cardiac events compared to a placebo in a large phase III international study. The study found no significant differences in cardiovascular death or heart attack rates between the two groups.
Researchers found that rivaroxaban is comparable to warfarin in preventing events in patients with bioprosthetic mitral valves and atrial fibrillation. Rivaroxaban was also shown to be superior to warfarin for a subgroup of patients with recent mitral valve replacement.
A recent study published in Science Advances found that baricitinib treatment significantly reduces mortality in COVID-19 patients with moderate to severe symptoms. The drug, commonly used for rheumatoid arthritis, was shown to block viral entry and reduce inflammation, leading to a 71% reduction in mortality rates.
A new medication has been shown to reduce the risk of heart failure-related events in patients with reduced ejection fraction. The study found that omecamtiv mecarbil, a novel heart medicine, had a greater effect on patients with lower ejection fractions.
A clinical trial found that fluvoxamine prevented COVID-19 infections from worsening and kept patients out of the hospital. The antidepressant drug reduced inflammation and protected against serious breathing difficulties, suggesting it may be a promising treatment for mild to moderate cases of COVID-19.
Brigham researchers present findings on the effectiveness of lipid-lowering therapies in reducing cardiovascular events and deaths in both younger and older patients. Additionally, a study reveals that over 80% of heart failure patients are eligible for recently FDA-approved SGLT2 inhibitor therapy.
A clinical study found that baricitinib reduced the rate of death or invasive mechanical ventilation in patients with severe COVID-19 by roughly half. The drug also restrained high ACE2 receptor expression in liver cells, helping to reduce viral infection.
A national study published in JAMA found that hydroxychloroquine did not improve clinical outcomes for adult patients hospitalized with respiratory illness related to COVID-19. The study, which enrolled 479 patients, showed no evidence that the drug prevented death or helped patients recover more quickly.
A single daily pill combining blood pressure and cholesterol medications with or without aspirin reduced cardiovascular disease events in people at intermediate risk for heart disease. The polypill plus aspirin combination lowered cardiovascular disease by 31%, compared to the polypill alone, which reduced it by 21%.
A new study published in Science Advances suggests that a type of arthritis drug called baricitinib can reduce the risk of dying from COVID-19 among elderly patients. The study found that patients who received the drug had a 71% reduced risk of death compared to those who did not receive it.
A recent study published in JAMA found that fluvoxamine may prevent serious breathing problems in people with mild COVID-19 illness. The results show that fluvoxamine has the potential to reduce the risk of hospitalization in COVID-19 patients.
Researchers found that fluvoxamine prevented serious clinical deterioration in COVID-19 patients with mild-to-moderate disease. The study, which involved 152 patients, showed that those treated with fluvoxamine were less likely to become seriously ill and require hospitalization.
Researchers found that C-section birth doubles asthma and allergy risk, but recovery of gut microbiota by age 1 may prevent this. The study suggests restoring the perturbed microbiome could prevent asthma development in high-risk children.
Two studies suggest that older adults aged 70 and over with elevated LDL cholesterol levels have the highest incidence of heart attacks and cardiovascular diseases. Cholesterol-lowering therapies, including statins, are as effective at reducing cardiovascular events in this age group as they are in younger people.
Using FDA-approved treatments increases the likelihood of success, but many smokers still struggle to quit. New research finds e-cigarettes containing nicotine are more effective than other therapies, including nicotine-free options and behavioral counseling.
A study analyzing over 20,000 participants found that healthy lifestyle behaviors decreased the risk of death regardless of medication usage. Higher numbers of healthy habits led to lower death risks.
A study of hospitalized COVID-19 patients with atrial fibrillation/flutter found a significantly higher risk of death and ICU mortality. However, meta-analyses examining the effect of renin-angiotensin-aldosterone system inhibitors on COVID-19 outcomes showed no increased risk of contracting COVID-19 or dying from the illness.
A Rutgers study found antipsychotic prescribing in young children is declining, but doctors continue to prescribe for conditions lacking FDA approval and without recommended psychiatric consultations. The study highlights the need for safer first-line psychosocial treatments to minimize risks associated with antipsychotic treatment.
A new study shows that the introduction of new cancer drugs between 2000 and 2016 led to a significant reduction in mortality rates for patients with 15 common types of cancer, including breast, lung, and colorectal cancer. The study estimates that these drug approvals saved over 1.2 million lives during this period.
Mavacamten improves key structural abnormalities in obstructive hypertrophic cardiomyopathy, reducing obstruction to blood flow and abnormal mitral valve motion. The treatment also decreases elevated filling pressures and restores normal cardiac structure and function.
A new medication, centhaquine, has been found safe and effective in treating severe blood or fluid loss caused by trauma. The study showed significant improvements in patient outcomes, including reduced mortality rates and improved blood pressure and organ function.
A new study published in the journal Brain found that patients with Parkinson's disease who experience tremor symptoms do not benefit from dopaminergic medication on their learning abilities. In contrast, patients without tremor show improvement in reward learning and faster deterioration of cognitive abilities.
Researchers found that tocotrienols extracted from palm oil activate Nrf2 nuclear translocation and increase the antioxidant-related hepatoprotective mechanism in mice liver cells. The study also showed that the effect is dose-dependent and functionally relevant.
A two-drug combination of dapagliflozin and exenatide continues to effectively control patients' glucose levels without losing efficacy over a two-year period. The study also revealed significant improvements in blood pressure and weight, contributing to overall health.
Researchers from Florida Atlantic University argue that remdesivir is justified for compassionate use in severely ill patients with COVID-19 due to its potential benefits in reducing recovery time. Despite FDA approval, the current evidence base supports the use of other proven preventive strategies such as social distancing and masking.
A new study examines clinical trials involving radiation therapy from 1996 to 2019 and finds that Black and Asian American patients are underrepresented, with 12% and 3% of trial participants respectively. The findings highlight the need for better inclusion of racial minorities in research studies.
Researchers have improved consistency assessment in meta-analysis by considering statistical power. This new measure can alter the interpretation of meta-analyses. Studies with high statistical power should have stronger effects on results.
A randomized trial will evaluate a telehealth-delivered collaborative care model to motivate primary care patients with opioid dependence and depression to increase engagement in evidence-based treatments. The study aims to improve depression symptoms and provide pragmatic clinical approaches to address this unmet challenge.
Researchers will present on anti-amyloid treatments and new late-stage clinical trials for Alzheimer's. NIA is funding over 230 active clinical trials to support the development of new treatments.
A double-blind clinical trial investigates the effectiveness of ondansetron, a cancer anti-sickness drug, in alleviating hallucinations in people with Parkinson's. The study aims to find new treatments for this challenging symptom, which affects 75% of UK Parkinson's patients.
Adagrasib achieves objective responses in nearly half of patients with non-small cell lung cancer; encouraging early results are seen in patients with colorectal, pancreatic, and endometrial cancer. The agent targets KRAS G12C mutation, leading to manageable side effects.
A clinical trial published in the New England Journal of Medicine shows that finerenone significantly slows the progression of diabetic kidney disease by 18% compared to a placebo. The study also found a reduction in cardiovascular event rates, offering new treatment options for patients with chronic kidney disease and type 2 diabetes.
A clinical trial called REPAIR-MDS will test repurposed drugs to improve hematological responses in MDS, reducing or reversing life-limiting deficiencies in red blood cells. The trial aims to improve the outlook for people with this rare condition, which has limited treatment options.
A new patient-reported outcome measure, SONG-HD Fatigue, has been validated to assess fatigue in patients receiving long-term dialysis treatments. The instrument calculates average fatigue over a period of 1 week, gauging tiredness, energy, and impact on life participation.
A new study found that malaria-preventive drugs can dramatically reduce infections in school children by half, leading to improved learning and reduced anemia. The analysis included 15,000 schoolchildren across seven African countries and showed a significant association between preventive treatment and better health outcomes.
A new study at Boston Medical Center found that the common treatment bevacizumab for diabetic macular edema is less effective for Black patients compared to white and Hispanic individuals. This disparity underscores the importance of increasing diversity in clinical trials to develop treatments tailored to all patient groups.
Two new UT Southwestern studies report that only half of practicing physicians are registered to vote, with time being the most common barrier faced by resident physicians. The researchers say finding ways to increase voter participation among doctors is critical as the nation tackles healthcare issues.
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) has achieved significant milestones in its first year, thanks to data sharing and collaboration among stakeholders. The platform serves as a centralized infrastructure to support data analysis and aid in the understanding of rare diseases.
A new study published in the New England Journal of Medicine found that tocilizumab does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19. The treatment was tested on 243 patients with high levels of inflammation and pneumonia, fever, or low ...
The VOYAGER PAD trial found that drug-coated devices do not increase mortality risk in patients with peripheral artery disease. Rivaroxaban use consistently reduced ischemic limb and cardiovascular outcomes regardless of device type.
A randomized trial comparing a nano-coated coronary stent with shorter dual anti-platelet therapy (DAPT) to a drug-eluting stent (DES) with guideline-recommended DAPT duration found no reduction in bleeding or thrombotic events. The study included 996 patients and found the rate of bleeding in the test group was 7.5% compared to 8.9% i...
The OPTIMIZE trial found that the new stent did not meet non-inferiority criteria due to high TVMI rates from high-sensitivity troponin biomarkers. However, independent analyses demonstrate non-inferiority with comparable relative non-inferiority margin, suggesting potential for improved clinical outcomes
The FORECAST trial found that fractional flow reserve derived from computed tomography coronary angiography (FFRCT) reduced the use of invasive coronary angiography by 22% without significantly reducing costs. The strategy also showed promise in terms of reducing healthcare utilization and improving patient outcomes.
A recent clinical trial found that patients with ALS who received the investigational neuroprotective therapy AMX0035 lived for a median of 6.5 months longer than those who received placebo. This result demonstrates the potential to prolong patient survival and slow disease progression.
A minimum unit price for alcohol policy significantly decreases deaths and hospitalizations related to alcohol use, according to a new report. By setting a floor price for alcohol sales, such policies help prevent the sale of cheap drinks with high alcohol content.
The 38th Annual Meeting of The Obesity Society will present innovative scientific research results through oral and poster abstracts. These communications highlight new anti-obesity medication clinical trials and comparisons of weight loss diets.
A new study found that 90% of CBD users claimed to use it for medical conditions such as autism, depression, and sleep disorders. In contrast, only 30% cited wellness benefits. The study highlights the need for enhanced regulation of the CBD market to prevent patients from forgoing proven treatments.
Aetion co-authored a study analyzing lethal coronaviruses SARS-CoV-2, SARS-CoV-1, and MERS-CoV to identify molecular characteristics of potential treatments. The study applied real-world data from COVID-19 patients to evaluate molecular hypotheses.
Researchers found that hypochlorous acid can chemically modify malodorous compounds and rapidly inactivate infectious particles, promoting greater latrine use. The study also shows potential for HOCl to improve latrine odor and reduce transmission of diseases such as dengue fever.
A review of 39 randomized clinical trials found that combining therapy with medication is more effective in preventing illness recurrence in people with bipolar disorder. Psychoeducation and group therapy were particularly helpful in reducing symptoms and improving outcomes.
A MU researcher developed a world's first health care transition readiness assessment for adolescents with autism, identifying skills needed for transition from pediatric care to adult care. The study found that young adults with autism can benefit from better understanding medication management, insurance policies and health care fina...
The NCI-MATCH trial, the largest precision medicine cancer trial to date, has made significant contributions to the use of tumor gene testing in selecting treatment for patients. The study found that nearly 40% of patients have matching tumor gene defects for targeted treatments.
The NIH has launched the ACTIV-5 Big Effect Trial to determine whether certain approved therapies or investigational drugs show promise against COVID-19. The study will enroll adult volunteers hospitalized with COVID-19 at up to 40 US sites and test three investigational treatments against a placebo.
Researchers found that older adults with heart failure are frequently prescribed 10 or more medications upon hospital discharge, leading to potential adverse effects. The study highlights the need for improved medication review processes to balance treatment benefits and risks.
Two studies from UC San Diego found that standing and light physical activity significantly reduce the risk of death, even for just 30 minutes a day. The research team also compared sedentary time in Americans to farmers in Malawi, finding substantially higher levels of activity among the latter group.
The study aims to examine the effectiveness of combining antiviral remdesivir with a highly concentrated solution of antibodies that neutralize SARS-CoV-2. The treatment is being tested in hospitalized adults with COVID-19 in various countries, with the goal of reducing the risk of serious illness and death.
The FDA has issued guidance on clinical trials for cancer drug development during the COVID-19 pandemic. The guidance highlights regulatory challenges and lessons learned from recent experiences. By providing this support, the FDA aims to facilitate oncology drug development in a challenging environment.
Researchers found that antibiotics were not worse than surgery in terms of overall health status, allowing most people to avoid operations. Patients treated with antibiotics often returned home faster but missed less time from work and school.